KOPS - The Institutional Repository of the University of Konstanz

Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy

Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy

Cite This

Files in this item

Checksum: MD5:3f043246e2f9099c46b8f89b7ee7cd1c

BASLER, Michael, Marcus GROETTRUP, 2020. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. In: Genes & Immunity. Springer Nature. 21(5), pp. 273-287. ISSN 1466-4879. eISSN 1476-5470. Available under: doi: 10.1038/s41435-020-00109-1

@article{Basler2020-11Recen-50694, title={Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy}, year={2020}, doi={10.1038/s41435-020-00109-1}, number={5}, volume={21}, issn={1466-4879}, journal={Genes & Immunity}, pages={273--287}, author={Basler, Michael and Groettrup, Marcus} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/50694"> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Basler, Michael</dc:contributor> <dc:creator>Groettrup, Marcus</dc:creator> <dcterms:issued>2020-11</dcterms:issued> <dc:creator>Basler, Michael</dc:creator> <dc:language>eng</dc:language> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dc:date> <dc:rights>terms-of-use</dc:rights> <dcterms:title>Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy</dcterms:title> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/50694"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dcterms:available> <dc:contributor>Groettrup, Marcus</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:abstract xml:lang="eng">The proteasome is a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells that controls numerous cellular processes through regulated protein degradation. Proteasome inhibitors have significantly improved the survival of multiple myeloma patients. However, clinically approved proteasome inhibitors have failed to show efficacy against solid tumors, neither alone nor in combination with other therapies. Targeting the immunoproteasome with selective inhibitors has been therapeutically effective in preclinical models for several autoimmune diseases and colon cancer. Moreover, immunoproteasome inhibitors prevented the chronic rejection of allogeneic organ transplants. In recent years, it has become apparent that inhibition of one single active center of the proteasome is insufficient to achieve therapeutic benefits. In this review we summarize the latest insights how targeting multiple catalytically active proteasome subunits can interfere with disease progression in autoimmunity, growth of solid tumors, and allograft rejection.</dcterms:abstract> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> </rdf:Description> </rdf:RDF>

Downloads since Sep 4, 2020 (Information about access statistics)

Basler_2-cd638k2zvyds2.pdf 2

This item appears in the following Collection(s)

Search KOPS


Browse

My Account